Breast Cancer Clinical Trial

Clinical Trial Finder Breast Cancer Trials

Companion Pharmacogenetic Study to UMCC 9900/9901

See Locations Near You

Summary

The purpose is to examine the original breast tumor material to see how much of a metabolizing enzyme (CYP3A4) is present in tumor material. The researchers want to see if this is in any way associated with how the patient responded to docetaxel. They also want to examine the genes in the tumor that are responsible for the production of CYP metabolizing enzymes, to see if they are normal or if they have polymorphisms, or change compared to 'normal' CYP metabolizing enzymes.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Patients who participated on UMCC 9900/9901
Living patients must give written informed consent

Exclusion Criteria:

No tumor block tissue available

Study is for people with:

Breast Cancer

Study ID:

NCT00146029

Recruitment Status:

Terminated

Sponsor:

University of Michigan Rogel Cancer Center

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

University of Michigan Cancer Center
Ann Arbor Michigan, 48109, United States

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Study ID:

NCT00146029

Recruitment Status:

Terminated

Sponsor:


University of Michigan Rogel Cancer Center

How clear is this clinincal trial information?

Clinical Trial Resources

SurvivorNet’s Guide To Clinical Trials: What Are They And Are They Right for You?
Clinical Trials for Breast Cancer
Have You Been Diagnosed With Late-Stage Breast Cancer? Know That You Have Treatment Options.
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider